GlassScriptPhysician profile
Geesala Garvin
NPI 1033466024
$4,602.92
in general payments reported to CMS, 2019-2025
17 companies · $751 in 2025
The $751 reported for 2025 was more than what 86% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $372 · 2020: $65.20 · 2021: $400 · 2022: $1,924 · 2023: $555 · 2024: $536 · 2025: $751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,786 · Entertainment: $55.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,786.00 |
| Entertainment | $55.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,071.25 | 2020-2025 | Tryptyr, Precision7, Total30 |
| Johnson & Johnson Vision Care, INC. | $439.33 | 2019-2025 | Acuvue |
| Sun Pharmaceutical Industries INC. | $252.80 | 2022-2024 | Cequa |
| Biotissue Holdings INC. | $228.43 | 2023-2025 | |
| Bausch & Lomb Americas INC. | $213.12 | 2023-2025 | Infuse Multifocal, Alden Scleral Zenlens, Infuse |
| Oyster Point Pharma, INC. | $190.84 | 2022-2023 | Tyrvaya |
| Johnson & Johnson Surgical Vision, INC. | $181.51 | 2019 | |
| Mallinckrodt Hospital Products INC. | $172.12 | 2022-2024 | Acthar |
| Glaukos Corporation | $171.41 | 2021-2024 | Photrexa |
| Tarsus Pharmaceuticals, INC. | $169.86 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $152.61 | 2019-2021 | |
| Dompe US, INC. | $150.23 | 2024-2025 | Oxervate |
| Optos, INC. | $55.83 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Abbvie INC. | $48.40 | 2022-2025 | |
| Allergan, INC. | $43.50 | 2020-2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $42.18 | 2022-2023 | |
| Coopervision INC. | $19.50 | 2023 | Myday Contact Lens |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geesala Garvin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.